Regulus Therapeutics (RGLS) versus Pluristem Therapeutics (PSTI) Head-To-Head Review

Pluristem Therapeutics (NASDAQ: PSTI) and Regulus Therapeutics (NASDAQ:RGLS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability and institutional ownership.

Volatility & Risk

How to Become a New Pot Stock Millionaire

Pluristem Therapeutics has a beta of 0.21, suggesting that its stock price is 79% less volatile than the S&P 500. Comparatively, Regulus Therapeutics has a beta of 1.72, suggesting that its stock price is 72% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Pluristem Therapeutics and Regulus Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pluristem Therapeutics 0 0 3 0 3.00
Regulus Therapeutics 0 4 2 0 2.33

Pluristem Therapeutics presently has a consensus target price of $4.00, suggesting a potential upside of 200.75%. Regulus Therapeutics has a consensus target price of $2.10, suggesting a potential upside of 188.46%. Given Pluristem Therapeutics’ stronger consensus rating and higher probable upside, research analysts clearly believe Pluristem Therapeutics is more favorable than Regulus Therapeutics.

Valuation & Earnings

This table compares Pluristem Therapeutics and Regulus Therapeutics’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Pluristem Therapeutics $2.85 million 51.38 -$27.81 million ($0.32) -4.16
Regulus Therapeutics $70,000.00 1,081.18 -$71.90 million ($1.11) -0.66

Pluristem Therapeutics has higher revenue and earnings than Regulus Therapeutics. Pluristem Therapeutics is trading at a lower price-to-earnings ratio than Regulus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

4.2% of Pluristem Therapeutics shares are owned by institutional investors. Comparatively, 53.7% of Regulus Therapeutics shares are owned by institutional investors. 7.0% of Pluristem Therapeutics shares are owned by company insiders. Comparatively, 4.8% of Regulus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Pluristem Therapeutics and Regulus Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Pluristem Therapeutics N/A -95.87% -77.80%
Regulus Therapeutics -99,868.07% -201.84% -92.58%

Summary

Pluristem Therapeutics beats Regulus Therapeutics on 10 of the 14 factors compared between the two stocks.

Pluristem Therapeutics Company Profile

Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The Company’s products include PLX-PAD and PLX R18. The Company’s PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The Company’s PLX products are administered using a standard needle and syringe. The Company’s PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women’s health diseases.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States. The company uses its microRNA product platform to develop anti-miRs, which are chemically modified and single-stranded oligonucleotides. Its clinical development products include RG-101, a GalNAc-conjugated anti-miR targeting miR-122 to treat patients with hepatitis C virus infection; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome; RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107 for the treatment of non-alcoholic fatty liver disease; RGLS5040, an anti-miR targeting microRNA-27 for the treatment of cholestatic disease; and RGLS4326, an anti-miR targeting microRNA-17 for the treatment of autosomal dominant polycystic kidney disease. The company has strategic alliance with AstraZeneca AB and Sanofi to discover, develop, and commercialize microRNA therapeutics; and Biogen Inc. on microRNA biomarkers for multiple sclerosis, as well as a clinical trial collaboration agreement with GSK LLC. It also has an oligonucleotide synthesis collaboration agreement with STA Pharmaceutical Co., Ltd. for research and mid-scale non-GMP/cGMP manufacturing. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.

Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Andujar, Stanton and Torres Shine in Yankees Rout
Andujar, Stanton and Torres Shine in Yankees Rout
Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Red Sox Tie Record for Best Start After 17 Games
Red Sox Tie Record for Best Start After 17 Games
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Rick Porcello’s Strong Start Gives Boost to Red Sox
Rick Porcello’s Strong Start Gives Boost to Red Sox
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry


Leave a Reply

 
© 2006-2018 BBNS.